UC Berkeley and other prominent academic institutions, including Johns Hopkins University in Maryland and Imperial College in London, are accelerating scientific research of psilocybin by launching a new center focusing on the compound (https://ibn.fm/VdvfN). Cybin (NEO: CYBN), a mushroom life science company, is positioned amid this growing research interest that is bringing psilocybin into mainstream. A recent article discussing the company reads, “Dedicated to supporting clinical studies across North America and other regions through strategic academic and institutional partnerships, including the Canadian Centre for Psychedelic Science, Cybin is poised to benefit from the increasing research interest in psilocybin. As an early entrant into a rapidly growing field, Cybin seems well positioned to leverage the growing recognition of psychedelic research leading to eventual public acceptance with the potential to propel the whole industry to the new level.”
To view the full article, visit https://ibn.fm/OCbFz
About Cybin Inc.
Cybin is a life sciences company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions. Cybin is developing technologies and delivery systems aiming to improve bioavailability to achieve the desired effects of psychedelics at low dosage levels. The new delivery systems are expected to be studied through clinical trials to confirm safety and efficacy. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
